Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Hepatitis C AND Hepatitis C

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    757 result(s) found for: Chronic Hepatitis C AND Hepatitis C. Displaying page 2 of 38.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023498-20 Sponsor Protocol Number: P07614 Start Date*: 2011-11-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b)
    Medical condition: Hepatitis type C (genotype I) virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000408-41 Sponsor Protocol Number: RNA003142-302 Start Date*: 2004-10-07
    Sponsor Name:Ribapharm, Inc.
    Full Title: RANDOMIZED, DOUBLE–BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF VIRAMIDINE TO RIBAVIRIN IN TREATMENT–NAïVE PATIENTS WITH CHRONIC HEPATITIS C
    Medical condition: Chronic Hepatitis C Viral Infection
    Disease: Version SOC Term Classification Code Term Level
    5.1 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002897-30 Sponsor Protocol Number: GS-US-334-0154 Start Date*: 2014-01-10
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2b Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003066-10 Sponsor Protocol Number: GS-US-342-4022 Start Date*: 2017-05-02
    Sponsor Name:Gilead Sciences International Ltd.
    Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and C...
    Medical condition: Chronic hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003001-42 Sponsor Protocol Number: GS-US-342-1522 Start Date*: 2016-01-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 weeks in Subjects with Chronic Hepatitis C Virus (HCV) infection
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003898-42 Sponsor Protocol Number: GS-US-342-1446 Start Date*: 2015-01-26
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002459-33 Sponsor Protocol Number: MEN_BOC Start Date*: 2011-12-06
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Boceprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1, either deemed Nonresponders to Peginterferon/Ribavirin...
    Medical condition: menopausal women with chronic HCV genotype1, naive or previously treated her with standard antiviral therapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003446-27 Sponsor Protocol Number: TMC435HPC3021 Start Date*: 2015-01-02
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or -Experienced Subj...
    Medical condition: Hepatitis C-Infection genotype 4 Patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-004138-41 Sponsor Protocol Number: TEL-PR Start Date*: 2012-12-10
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution?
    Medical condition: Chronic active hepatitis C never treated previously with anti-HCV therapies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000417-73 Sponsor Protocol Number: GS-US-342-2097 Start Date*: 2016-07-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subje...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003741-42 Sponsor Protocol Number: GS-US-337-1904 Start Date*: 2018-10-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Underg...
    Medical condition: Hepatitis C Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002641-11 Sponsor Protocol Number: GS-US-334-0153 Start Date*: 2013-10-07
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 ...
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000179-98 Sponsor Protocol Number: GS-US-367-4181 Start Date*: 2017-06-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treat...
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    19.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002457-29 Sponsor Protocol Number: GS-US-334-0125 Start Date*: 2013-01-08
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 24 weeks in Patients Infected with Chronic HCV with Cirrhosis a...
    Medical condition: Subjects infected with chronic HCV with cirrhosis and portal hypertension with or without liver decompensation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004713-24 Sponsor Protocol Number: GECOMstudy Start Date*: 2016-04-11
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 (Grazoprevir) / MK8742 (Elbasvir) Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection...
    Medical condition: Chronic infection with Hepatitis C virus genotype 1b with compensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004871 10064844 Compensated cirrhosis LLT
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003956-22 Sponsor Protocol Number: GS-US-337-2091 Start Date*: 2017-09-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003570-32 Sponsor Protocol Number: GS-US-337-1115 Start Date*: 2015-08-14
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Granules Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    18.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003340-72 Sponsor Protocol Number: 5172-39 Start Date*: 2013-05-14
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2016-002608-19 Sponsor Protocol Number: 64294178HPC3001 Start Date*: 2017-06-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C...
    Medical condition: Chronic Hepatitis C virus infection.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001130-13 Sponsor Protocol Number: Start Date*: 2007-12-05
    Sponsor Name:Malmö University Hospital
    Full Title: Hepatitis C in a cohort of patients with maintenance therapy for opiate dependence - prevalence, severity and outcome of antiviral therapy
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 13:54:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA